OBJECTIVES: Benefits of treatment are often expressed as quality-adjusted life years (QALYs). A QALY attempts to capture benefit in terms of both quantity of survival and quality of life (QoL). Where appropriate data has not been captured in a trial context, other methods need to be applied. The aim of this study was to capture QoL data in the form of health state utilities, ranging from 0 (dead) to 1 (full health), for outcomes associated with receiving therapy for rel/ref HL and sALCL. These utilities could be used to support economic evaluation of future treatments. METHODS: Health state descriptions or ‘vignettes’ were developed (with patient and clinician input) depicting the burden associated with various stages of rel/ref HL or sALCL, degree of disease response (complete [CR] or partial response, stable or progressive disease), and adverse events (AE) experienced (B-symptoms, acute/chronic graft-versus-host disease [GVHD], grade I/II or grade III peripheral sensory neuropathy). Vignettes were then valued by 75 members of the general public in Taiwan, Thailand, and South Korea using the time trade-off (TTO) methodology to elicit utility values. RESULTS: Disease experience was associated with a significant decline in QoL. Even a CR demonstrated a notable negative impact on QoL (Taiwan 0.597, Thailand 0.728, South Korea 0.827). The experience of any AE was associated with substantial disutility, the most burdensome generally being acute GVHD (Taiwan 0.199, Thailand 0.124, South Korea 0.347). Additionally, progressive disease was valued as having a very severe impact on QoL (Taiwan 0.229, Thailand 0.071, South Korea 0.317). CONCLUSIONS: Experience of rel/ref HL and sALCL is viewed as potentially devastating by individuals in all three countries. However, variations do exist between regions, suggesting that individuals may approach the TTO exercise differently. The results of this study may have important implications for the economic evaluation of future treatments.